Clinical trials: Skin Diseases, Papulosquamous
Psoriasis
The Effects of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis (Study P04271AM2)(COMPLETED)
This is a Phase 3b, randomized, parallel-group, multicenter, active-controlled, open-label study of the efficacy and safety of infliximab compared with methotrexate (MTX) in the treatment of moderate to severe psoriasis in adults…
- Trial name
- NCT00251641
- Testing
- infliximab, methotrexate
- Volunteers
- 868 people
- Sponsor
- Merck Sharp & Dohme LLC
Psoriasis
The Immunological Basis for Treatment Resistance to Anti-TNF Treatments
The purpose of this study is to determine the relationship between two types of cell signals, type I interferon (IFN) and tumor necrosis factor (TNF), in psoriatic skin prior to and during treatment with etanercept and correlate…
- Trial name
- NCT01971346
- Testing
- etanercept
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Psoriasis
Adalimumab in Adult Japanese Subjects With Psoriasis
To evaluate efficacy, safety, and pharmacokinetics of adalimumab in Japanese participants with psoriasis
- Trial name
- NCT00647400
- Testing
- adalimumab
- Where
- 64 sites in Japan
- Volunteers
- 147 people
- Sponsor
- Abbott
Down Syndrome, Alopecia Areata
Tofacitinib for Immune Skin Conditions in Down Syndrome
People with Down syndrome (DS) display widespread immune dysregulation, including several immune skin conditions. This study hypothesizes that pharmacological inhibition of the increased interferon (IFN) signaling seen in DS is…
- Conditions
- Down Syndrome, Alopecia Areata, Atopic Dermatitis / Eczema, Hidradenitis Suppurativa
- Trial name
- NCT04246372
- Testing
- Tofacitinib
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- University of Colorado, Denver
Rheumatoid Arthritis, Psoriatic Arthritis
Study to Characterize Demographics, Compliance, Tolerability and Safety in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Prescribed Adalimumab (Humira®) as Part of Routine Clinical Care
The primary objective of this post-marketing observational study was to obtain data on the characteristics (patient age/gender; disease type, severity and duration; disease specific treatment history; current concomitant…
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis
- Trial name
- NCT01163916
- Where
- 43 sites in Russia
- Volunteers
- 252 people
- Sponsor
- Abbott
Generalized Pustular Psoriasis, Erythrodermic Psoriasis
A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
The purpose of this study is to evaluate how effective JNJ-77242113 is in participants with generalized pustular psoriasis (GPP) or erythrodermic psoriasis (EP).
- Trial name
- NCT06295692
- Testing
- JNJ-77242113
- Where
- 12 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Janssen Pharmaceutical K.K.
Palmoplantar Pustulosis
A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis
- Trial name
- NCT03988335
- Testing
- RIST4721
- Where
- 17 sites in Canada, Germany
- Volunteers
- 35 people
- Sponsor
- Aristea Therapeutics, Inc.
Moderate to Severe Psoriasis
Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab Therapy
Adalimumab has recently been authorized for active psoriasis in Peru and local experience is very low. The aim of this study is to obtain Peruvian data of clinical effectiveness and impact on health-related quality of life with…
- Trial name
- NCT01156532
- Where
- 3 sites in Peru
- Volunteers
- 30 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriasis Guttate, Plaque Psoriasis
Guselkumab Immunogenetics
This is a two-arm open-label study to evaluate the clinical and immunogenetic responses of patients with plaque or guttate psoriasis to treatment with guselkumab.
- Trial name
- TIG (NCT04645355)
- Testing
- Guselkumab
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Psoriasis
Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis
The purpose of the study is to investigate if combined use of OLUX-E™ Foam and SORILUX Foam may help "maintain" the therapeutic benefit that is achieved with OLUX-E™ Foam in the treatment of moderate plaque psoriasis.
- Trial name
- NCT01745133
- Testing
- vehicle foam, calcipotriene, calcipotriene + clobetasol propionate
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Leon Kircik, M.D.
Psoriasis
Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
The purpose of this study is to determine the effectiveness and safety, over 12 weeks, of 3 dosing regimens of CP-690,550 for the treatment of adults with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT00678210
- Testing
- CP-690,550
- Where
- 44 sites in United States, Canada
- Volunteers
- 197 people
- Sponsor
- Pfizer